Paolo Tarantino: What percentage of our patients with ER+/HER2- eBC may qualify for adjuvant CDK4/6i?

Paolo Tarantino shared a post on X:

“Now that adjuvant ribociclib is approved, what % of our patients with ER+/HER2- eBC may qualify for adjuvant CDK4/6i?

We just presented at ESMO24 the results of our real-world study:
~10% of pts with N0 disease
~100% with N1-3 disease.”

Full poster here.

Sarah Sammons shared the post, replying:

“75% of early stage HR+ breast cancer is node negative. Of those, only 10% will meet criteria for Ribociclib based on risk.”

Source: Paolo Tarantino/X and Sarah Sammons/X

Sarah Sammons is a medical oncologist at Dana-Farber’s Breast Oncology Center specializing in treating patients with all stages of breast cancer. She is particularly focusing on improving outcomes for those with metastatic breast cancer. Through leading numerous clinical trials, she has developed new treatment options for breast cancer patients. Additionally, Dr. Sammons is skilled in treating brain metastases.

Dr. Paolo Tarantino, MD, is pursuing an advanced research fellowship at Dana-Farber Cancer Institute and Harvard Medical School, concurrently working towards a PhD in clinical research at the University of Milan. His research focuses on exploring the HER2 oncoprotein, investigating the emerging HER2-low subgroup of breast tumors, and developing novel antibody-drug conjugates targeting every subtype of breast cancer. With a  publication record exceeding 50 papers on breast cancer, he is recognized as a leading expert in the field.